Caldera, a clinical stage biotechnology company developing the first-in-class bispecific antibody CLD-423 for inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases, launched with $112.5 million total capital raised and announced that the first subjects have been dosed in the Phase 1 trial of its lead program, CLD-423. Caldera raised a $75 million Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5 million Series A-1 round led by Omega Funds, with participation from new investors Wellington Management and Janus Henderson Investors.